Clover Biopharma adds $230M as Covid-19 vaccine heads to pivotal test

Published on:

Vial and syringe with a vaccine

The protein-based Covid-19 vaccine from Clover Biopharmaceuticals has distribution and storage advantages compared to messenger RNA vaccines. If the vaccine succeeds in a Phase 2/3 test, China-based Clover will distribute it globally via COVAX.

Read more    Source: medcitynews.com

Leave a Reply